Adlai Nortye Group Ltd.

Adlai Nortye Group Ltd.에 대해 보유한 최신 분기

기업이 직접 제출한 6-K에서 가져왔습니다.

경영진의 발언

“We continue to execute well across our pipeline, with initial clinical data on track for both of our pan-RAS(ON) inhibitor-based assets in 2027,”

발표 자료에서 그대로 인용했으며, 공시가 발언자를 실명으로 밝힌 경우에만 표시합니다.

Adlai Nortye Group Ltd.은(는) 무엇을 하는 기업인가

Adlai Nortye is a global clinical-stage biopharmaceutical company dedicated to developing innovative cancer therapies. The global infrastructure supports the efficient execution of our robust pipeline of drug candidates covering two key therapeutic areas: 1) Precision RAS pathway targeted therapies: including the oral pan-RAS(ON) inhibitor AN9025, and the CEACAM5-targeting ADC AN4035 engineered from the Company’s proprietary RASiCA™ (RAS Inhibitor Conjugated Antibody) platform, which efficiently delivers a potent pan-RAS(ON) inhibitor to the tumor site. 2) Next-generation PD-1/L1 pathway modulating immunotherapies: including AN8025, a multi-functional fusion protein that simultaneously modulates T cells and antigen-presenting cells. 4

발표 자료 말미에 실린 기업 자신의 소개글입니다.